AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373

Rhea-AI Filing Summary

AtriCure, Inc. director Karen Prange reported an open-market sale of 3,000 shares of common stock on May 20, 2026 at a weighted average price of $28.65 per share. After this transaction, she directly holds 26,373 shares of AtriCure common stock.

The sale was executed in multiple trades within a price range of $28.60 to $28.76 per share, with the reported price reflecting the weighted average sales price.

Insights

Equity governance analyst

Director makes a modest open-market sale while retaining a sizable share position.

Director Karen Prange sold 3,000 shares of AtriCure common stock in an open-market transaction at a weighted average price of $28.65 per share. This is a straightforward disposition with no derivatives or complex instruments involved.

Following the sale, she continues to hold 26,373 shares directly, indicating she maintains a meaningful equity stake. The filing notes the sale was split across multiple trades between $28.60 and $28.76 per share, but does not reference any trading plan or derivative positions in this excerpt.

Insider Trade Summary

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Prange Karen

Role Director

Sold 3,000 shs ($86K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$28.65	$86K

Holdings After Transaction: Common Stock — 26,373 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $28.60 to $28.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 3,000 shares Weighted average sale price: $28.65 per share Post-transaction holdings: 26,373 shares +1 more

4 metrics

Shares sold 3,000 shares Open-market sale on May 20, 2026

Weighted average sale price $28.65 per share Common stock sale on May 20, 2026

Post-transaction holdings 26,373 shares Shares directly owned after sale

Trade price range $28.60–$28.76 per share Multiple trades underlying the reported average price

Key Terms

open-market sale, weighted average sales price, non-derivative, Common Stock

4 terms

open-market sale financial

"reported an open-market sale of 3,000 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"The price reported above reflects the weighted average sales price."

non-derivative financial

"transaction_type": "non-derivative""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/22/2026 - 08:57 AM Learn about SEC filing dates

FAQ

What insider transaction did AtriCure (ATRC) director Karen Prange report?

Director Karen Prange reported an open-market sale of 3,000 AtriCure common shares. The transaction occurred on May 20, 2026 at a weighted average price of $28.65 per share, reflecting multiple trades within a narrow intraday price range.

At what price did Karen Prange sell AtriCure (ATRC) shares in this Form 4?

She sold the shares at a weighted average price of $28.65 per AtriCure share. The Form 4 explains the sale was executed in multiple trades between $28.60 and $28.76, with the reported figure representing the volume-weighted average.

How many AtriCure (ATRC) shares does Karen Prange hold after the reported sale?

After the sale, Karen Prange directly holds 26,373 AtriCure common shares. This post-transaction figure, disclosed in the Form 4, helps investors understand that she retains a notable ongoing equity position in the company despite selling 3,000 shares.

Was the AtriCure (ATRC) insider sale done in a single trade or multiple trades?

The sale was executed in multiple trades rather than a single block. The Form 4 footnote states the trades occurred between $28.60 and $28.76 per share, with the disclosed $28.65 price representing the weighted average sales price for the 3,000 shares.

Does the AtriCure (ATRC) Form 4 mention any derivative securities for Karen Prange?

No derivative securities are listed for this transaction in the provided Form 4 data. The filing shows only a non-derivative transaction in AtriCure common stock and indicates no remaining derivative positions in the accompanying derivative summary section.

What does an open-market sale mean in Karen Prange’s AtriCure (ATRC) filing?

An open-market sale means the 3,000 AtriCure shares were sold on the public market at prevailing prices. The Form 4 classifies the transaction as an open-market sale, indicating a standard stock market trade rather than a private or off-market transfer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prange Karen

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		S		3,000	D	$28.65(1)	26,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $28.60 to $28.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Karen N. Prange	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)